Andrea Vingiani

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7098258/publications.pdf

Version: 2024-02-01

49 2,986 21 45
papers citations h-index g-index

51 51 51 4895
all docs docs citations times ranked citing authors

#	Article	IF	CITATIONS
1	Fasting-Mimicking Diet Is Safe and Reshapes Metabolism and Antitumor Immunity in Patients with Cancer. Cancer Discovery, 2022, 12, 90-107.	7.7	124
2	Copy number alterations analysis of primary tumor tissue and circulating tumor cells from patients with early-stage triple negative breast cancer. Scientific Reports, 2022, 12, 1470.	1.6	10
3	Tumor infiltrating lymphocyte stratification of prognostic staging of early-stage triple negative breast cancer. Npj Breast Cancer, 2022, 8, 3.	2.3	33
4	Correlation between radiological and biological features and clinical outcomes in early prostate cancer: an exploratory subgroup analysis. Neoplasma, 2022, , .	0.7	0
5	Acquired Resistance Mechanisms to PD-L1 Blockade in a Patient With Microsatellite Instability-High Extrahepatic Cholangiocarcinoma. JCO Precision Oncology, 2022, 6, e2100472.	1.5	2
6	Exceptional tumour responses to fasting-mimicking diet combined with standard anticancer therapies: A sub-analysis of the NCT03340935 trial. European Journal of Cancer, 2022, 172, 300-310.	1.3	19
7	Transplantation of autologous extracellular vesicles for cancer-specific targeting. Theranostics, 2021, 11, 2034-2047.	4.6	32
8	Detection of Genomically Aberrant Cells within Circulating Tumor Microemboli (CTMs) Isolated from Early-Stage Breast Cancer Patients. Cancers, 2021, 13, 1409.	1.7	9
9	Circulating Tumor Cell Clusters Are Frequently Detected in Women with Early-Stage Breast Cancer. Cancers, 2021, 13, 2356.	1.7	26
10	Malignant salivary gland tumours in families with breast cancer susceptibility. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2021, 479, 221-226.	1.4	0
11	Genomic and Transcriptomic Analyses of Breast Cancer Primaries and Matched Metastases in AURORA, the Breast International Group (BIG) Molecular Screening Initiative. Cancer Discovery, 2021, 11, 2796-2811.	7.7	79
12	Targeting lipid metabolism is an emerging strategy to enhance the efficacy of anti-HER2 therapies in HER2-positive breast cancer. Cancer Letters, 2021, 511, 77-87.	3.2	22
13	Cancer-derived EVs show tropism for tissues at early stage of neoplastic transformation. Nanotheranostics, 2021, 5, 1-7.	2.7	13
14	Cancer Associated Fibroblasts and Senescent Thyroid Cells in the Invasive Front of Thyroid Carcinoma. Cancers, 2020, 12, 112.	1.7	30
15	A cell-of-origin epigenetic tracer reveals clinically distinct subtypes of high-grade serous ovarian cancer. Genome Medicine, 2020, 12, 94.	3.6	11
16	Clinical performance of contrast-enhanced spectral mammography in pre-surgical evaluation of breast malignant lesions in dense breasts: a single center study. Breast Cancer Research and Treatment, 2020, 184, 723-731.	1.1	20
17	Hormone Receptor Loss in Breast Cancer: Molecular Mechanisms, Clinical Settings, and Therapeutic Implications. Cells, 2020, 9, 2644.	1.8	30
18	Contrast-enhanced mammography in the evaluation of breast calcifications: preliminary experience. Tumori, 2020, 106, 491-496.	0.6	8

#	Article	IF	CITATIONS
19	Tumor-infiltrating lymphocytes (TILs) in ER+/HER2â ⁻² breast cancer. Breast Cancer Research and Treatment, 2020, 183, 347-354.	1.1	59
20	Prognostic and predictive value of cell cycle progression (CCP) score in ductal carcinoma in situ of the breast. Modern Pathology, 2020, 33, 1065-1077.	2.9	3
21	Tumor Biomarkers for the Prediction of Distant Metastasis in Head and Neck Squamous Cell Carcinoma. Cancers, 2020, 12, 922.	1.7	12
22	Ductal carcinoma in situ and intraoperative partial breast irradiation: Who are the best candidates? Long-term outcome of a single institution series. Radiotherapy and Oncology, 2019, 133, 68-76.	0.3	9
23	Towards mm-wave spectroscopy for dielectric characterization of breast surgical margins. Breast, 2019, 45, 64-69.	0.9	28
24	Tumor-Infiltrating Lymphocytes and Prognosis: A Pooled Individual Patient Analysis of Early-Stage Triple-Negative Breast Cancers. Journal of Clinical Oncology, 2019, 37, 559-569.	0.8	505
25	Targeted-Gene Sequencing to Catch Triple Negative Breast Cancer Heterogeneity before and after Neoadjuvant Chemotherapy. Cancers, 2019, 11, 1753.	1.7	16
26	Endocrine-responsive lobular carcinoma of the breast: features associated with risk of late distant recurrence. Breast Cancer Research, 2019, 21, 153.	2.2	10
27	Prognostic implications of residual disease tumor-infiltrating lymphocytes and residual cancer burden in triple-negative breast cancer patients after neoadjuvant chemotherapy. Annals of Oncology, 2019, 30, 236-242.	0.6	123
28	The developmental origins of high grade serous ovarian cancer Journal of Clinical Oncology, 2019, 37, e17063-e17063.	0.8	0
29	Tumor infiltrating lymphocytes in early breast cancer. Breast, 2018, 37, 207-214.	0.9	108
30	Oncological Outcomes of Nipple-Sparing Mastectomy: A Single-Center Experience of 1989 Patients. Annals of Surgical Oncology, 2018, 25, 3849-3857.	0.7	68
31	Analysis of Efficacy and Accuracy of 2 Vacuum-Assisted Breast Biopsy Devices: Mammotome and Elite. Clinical Breast Cancer, 2018, 18, e1277-e1282.	1.1	16
32	Enhancer mapping uncovers phenotypic heterogeneity and evolution in patients with luminal breast cancer. Nature Medicine, 2018, 24, 1469-1480.	15.2	98
33	Unfavorable prognostic role of tumor-infiltrating lymphocytes in hormone-receptor positive, HER2 negative metastatic breast cancer treated with metronomic chemotherapy. Breast, 2017, 34, 83-88.	0.9	22
34	The prevalence and clinical relevance of tumor-infiltrating lymphocytes (TILs) in ductal carcinoma in situ of the breast. Annals of Oncology, 2017, 28, 321-328.	0.6	72
35	Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Carcinomas, Nonâ€"Small Cell Lung Carcinoma and Mesothelioma, Endometrial and Ovarian Carcinomas, Squamous Cell Carcinoma of the Head and	2.4	530
36	Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: Advances in Anatomic Pathology, 2017, 24. Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method From the International Immunooncology Biomarkers Working Group: Part 1: Assessing the Host Immune Response, TILs in Invasive Breast Carcinoma and Ductal Carcinoma In Situ, Metastatic Tumor Deposits and Areas for Further Research. Advances in Anatomic Pathology, 2017, 24, 235-251.	2.4	469

3

#	Article	IF	CITATIONS
37	Prognostic value of tumour-infiltrating lymphocytes in small HER2-positive breast cancer. European Journal of Cancer, 2017, 87, 164-171.	1.3	7
38	The Pathology Report. , 2017, , 157-168.		1
39	The Stearoyl-CoA Desaturase-1 (Desat1) in Drosophila cooperated with Myc to Induce Autophagy and Growth, a Potential New Link to Tumor Survival. Genes, 2017, 8, 131.	1.0	9
40	<i>ROS1</i> Gene Fusion in Advanced Lung Cancer in Women: A Systematic Analysis, Review of the Literature, and Diagnostic Algorithm. JCO Precision Oncology, 2017, 1, 1-9.	1.5	9
41	Solitary thyroid metastasis from colon cancer: a rare case report. Ecancermedicalscience, 2016, 10, 696.	0.6	4
42	Tumor-infiltrating lymphocytes (TILs) are a powerful prognostic marker in patients with triple-negative breast cancer enrolled in the IBCSG phase III randomized clinical trial 22-00. Breast Cancer Research and Treatment, 2016, 158, 323-331.	1.1	100
43	Biomarkers for the identification of recurrence in human epidermal growth factor receptor 2-positive breast cancer patients. Current Opinion in Oncology, 2016, 28, 476-483.	1.1	6
44	Clinical validity of tumor-infiltrating lymphocytes analysis in patients with triple-negative breast cancer. Annals of Oncology, 2016, 27, 249-256.	0.6	125
45	Tumour infiltrating lymphocytes (TILs) in breast cancer during pregnancy. Breast, 2015, 24, 290-293.	0.9	27
46	Effect of Metformin on Breast Ductal Carcinoma <i>In Situ</i> Proliferation in a Randomized Presurgical Trial. Cancer Prevention Research, 2015, 8, 888-894.	0.7	23
47	The clinical relevance of micropapillary carcinoma of the breast: a case–control study. Histopathology, 2013, 63, 217-224.	1.6	53
48	ecancermedicalscience. Ecancermedicalscience, 2012, 6, 253.	0.6	3
49	Salivary gland choristoma in large bowel. Endoscopy, 2012, 44, E13-E14.	1.0	3